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ABSTRACT
Objectives Determine the efﬁcacy and safety of daily
lesinurad (200 or 400 mg orally) added to allopurinol in
patients with serum uric acid (sUA) above target in a
12-month, randomised, phase III trial.
Methods Patients on allopurinol ≥300 mg (≥200 mg
in moderate renal impairment) had sUA level of
≥6.5 mg/dL (≥387 mmol/L) at screening and two or
more gout ﬂares in the prior year. Primary end point was
the proportion of patients achieving sUA level of
<6.0 mg/dL (<357 mmol/L) (month 6). Key secondary
end points were mean gout ﬂare rate requiring treatment
(months 7 through 12) and proportions of patients with
complete resolution of one or more target tophi (month
12). Safety assessments included adverse events and
laboratory data.
Results Patients (n=610) were predominantly male,
with mean (±SD) age 51.2±10.90 years, gout duration
11.5±9.26 years and baseline sUA of 6.9±1.2 mg/dL
(410±71 mmol/L). Lesinurad at 200 and 400 mg doses,
added to allopurinol, signiﬁcantly increased proportions
of patients achieving sUA target versus allopurinol-alone
therapy by month 6 (55.4%, 66.5% and 23.3%,
respectively, p<0.0001 both lesinurad+allopurinol
groups). In key secondary end points, there were no
statistically signiﬁcant treatment-group differences
favouring lesinurad. Lesinurad was generally well
tolerated; the 200 mg dose had a safety proﬁle
comparable with allopurinol-alone therapy. Renal-related
adverse events occurred in 5.9% of lesinurad 200 mg
+allopurinol, 15.0% of lesinurad 400 mg+allopurinol
and 4.9% of allopurinol-alone groups, with serum
creatinine elevation of ≥1.5× baseline in 5.9%, 15.0%
and 3.4%, respectively. Serious treatment-emergent
adverse events occurred in 4.4% of lesinurad 200 mg
+allopurinol, in 9.5% of lesinurad 400 mg+allopurinol
and in 3.9% of allopurinol-alone groups, respectively.
Conclusion Lesinurad added to allopurinol
demonstrated superior sUA lowering versus allopurinol-
alone therapy and lesinurad 200 mg was generally well
tolerated in patients with gout warranting additional
therapy.
Trial registration number NCT01493531.
INTRODUCTION
Gout is an inﬂammatory arthritis characterised by
the deposition of monosodium urate (MSU) crystals
in the joints, tendons and other connective tissues.
Crystal deposition secondary to long-standing
hyperuricemia can be reversed by lowering the con-
centration of serum uric acid (sUA) below the MSU
saturation point—leading, in the long term, to the
potential disappearance of signs and symptoms of
gout. As a result, current management guidelines
recommend maintenance of sUA to <6.0 mg/dL
(<357 mmol/L) in patients with gout.1–3
Allopurinol is recommended as a ﬁrst-line urate-
lowering therapy (ULT).2 4 However, clinical trials
have demonstrated that >50% of patients do not
achieve sustained reductions in sUA at the most
commonly used allopurinol dose of 300 mg.5–8
Lesinurad (RDEA594) is a novel, selective uric acid
reabsorption inhibitor (SURI) for treatment of gout
in combination with xanthine oxidase inhibitors.
Lesinurad inhibits URAT1, a uric acid transporter
responsible for the reabsorption of uric acid from
the renal tubular lumen.9–11 Lesinurad in combin-
ation with allopurinol therefore provides a dual
mechanism for sUA lowering—an increase in excre-
tion of uric acid and a reduction in urate production.
Clinical studies have demonstrated that lesinurad
in combination with allopurinol reduces mean
sUA concentrations and increases proportions of
patients who achieve sUA targets.12–14 The current
phase III study—Combining Lesinurad with
Allopurinol Standard of Care in Inadequate
Responders (CLEAR 2)—is one of two replicate,
randomised, double-blind, placebo-controlled, mul-
ticentre studies to investigate lesinurad in combin-
ation with allopurinol in patients with gout.
CLEAR 1 was performed within the USA, included
603 patients with gout and provided outcomes
similar to the CLEAR 2 study.15
METHODS
Study design
CLEAR 2 was an international, phase III trial to
investigate the efﬁcacy and safety of two lesinurad
doses (200 or 400 mg oral, once daily) in combin-
ation with allopurinol, versus allopurinol combined
with placebo (the control arm), in patients
demonstrating inadequate response to standard-
of-care allopurinol (ClinicalTrials.gov Identiﬁer:
NCT01493531). The study was conducted in 12
countries in Europe, North America, South Africa,
Australia and New Zealand between December
2011 and July 2014.
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CLEAR 2 included a screening period of approximately
28 days, including a run-in of approximately 14 days on gout ﬂare
prophylaxis and 12-month double-blind treatment (ﬁgure 1). The
study was conducted in accordance with Independent Ethics
Committee E6 Good Clinical Practice, the Declaration of
Helsinki (October 2008) and all applicable local regulatory
requirements.
Patients
Male or female patients aged 18–85 years with a diagnosis of
gout, body mass index <45 kg/m2, inadequate hypouricaemic
response to standard-of-care allopurinol and two or more gout
ﬂares in the previous 12 months were eligible for study inclu-
sion. Patients were included if they met the 1977 American
Rheumatism Association preliminary classiﬁcation criteria for
gout.16 Patients were required to have received allopurinol as
the sole ULT for ≥8 weeks prior to screening at a dose assessed
medically appropriate by the treating physician (minimum
300 mg/day (200 mg in moderate renal impairment)17 up to
800 or 900 mg, depending on locally approved dose). sUA was
required to be ≥6.5 mg/dL (≥387 mmol/L) at screening and
≥6.0 mg/dL (≥357 mmol/L) approximately 7 days prior to start
of treatment on day 1.
Patients with estimated creatinine clearance (eCrCl) <30 mL/
min were excluded from study. Patients with a history of kidney
stones were permitted. Complete exclusion criteria are included
in the online supplementary material 1.
Study medications
Eligible patients were randomised by double-blind method to
one of three treatment groups (lesinurad 200 mg, lesinurad
400 mg or placebo) in 1:1:1 ratio, added to continued treatment
with allopurinol at pre-study dose. Randomisation at study sites
used a centralised Interactive Voice Response System/Interactive
Web Response System.
Doses of lesinurad or matching placebo were taken once daily
in the morning with food and one cup of water. Compliance
was assessed from dispensing records and veriﬁcation of
returned medication packaging. Concomitant medication use
was recorded at each study visit.
Gout ﬂare prophylaxis was initiated at day −14, that is, the
same time as sponsor-provided allopurinol. Prophylaxis con-
sisted of colchicine (0.5 or 0.6 mg/day, as locally available) or a
non-steroidal anti-inﬂammatory drug (NSAID, dosed according
to local prescribing practice, with or without proton-pump
inhibitor) for patients who were intolerant to or had contraindi-
cations to colchicine. Gout ﬂare prophylaxis was continued
through month 5, unless patients became intolerant or devel-
oped toxicity to prophylaxis.
Patients were encouraged to drink 2 L of ﬂuid a day and
remain well hydrated, following American College of
Rheumatology guidelines for management of gout.2
Assessments
Efﬁcacy assessments
The primary efﬁcacy end point was the proportion of patients
in each treatment group with sUA <6.0 mg/dL (<357 mmol/L)
by month 6. Other sUA-related end points included proportions
of patients with sUA <6.0 mg/dL (<357 mmol/L), <5.0 mg/dL
(<297 mmol/L) and <4.0 mg/dL (<238 mmol/L) and mean
absolute and mean percentage changes from baseline in sUA at
each visit.
Two key secondary end points included: (1) mean rate of
gout ﬂares requiring treatment for the 6-month period from
end of month 6 to end of month 12, reported on a daily elec-
tronic patient diary. This key secondary end point included only
Figure 1 CLEAR 2 trial design is shown. *200 mg permitted for renally impaired. Maximum allopurinol dose: 800 or 900 mg, according to local
label. Randomisation was stratiﬁed at day −7 by renal function (ie, estimated eCrCl ≥60 vs <60 mL/min, calculated by the Cockcroft-Gault formula
using ideal body weight) and by tophus status during screening (ie, one or more tophus versus no tophi). eCrCl, estimated creatinine clearance; sUA,
serum uric acid.
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clinically relevant gout ﬂares, which were those requiring either
an increase in current medication or new medication and (2)
proportion of patients with target tophi at baseline who experi-
enced complete resolution of one or more target tophi by
month 12, that is, 100% decrease in tophus area. Target tophi
(up to ﬁve per patient) were tophi on the hands/wrists and/or
feet/ankles measured by digital Vernier callipers at ≥5 and
≤20 mm in longest diameter.18 Permitted treatments for gout
ﬂares were colchicine, analgesics and/or anti-inﬂammatory medi-
cations, including oral and intra-articular corticosteroids.
Safety assessments
Safety assessments included treatment-emergent adverse events
(TEAEs; coded by Medical Dictionary for Regulatory Activities
(V.14.0)), clinical laboratory data, physical examination, ECG
and vital signs. Adverse events (AEs) of special interest included
renal and cardiovascular (CV) safety assessments.
Assessments of renal safety included renal-related and kidney
stone TEAEs (see online supplementary material 2) and clinical
laboratory data, including serum creatinine (sCr), creatine
kinase, urine protein-to-creatinine ratio and eCrCl levels. CV
safety was of special interest because of the known high rates of
CV risk factors in patients with gout.19 20 An independent
Cardiovascular Events Adjudication Committee (CEAC) rou-
tinely assessed AEs for potential CV relationship, with categor-
isation into major adverse CV events (MACEs) and non-MACE
end points (see online supplementary material 3).21
Statistical analyses
Comparisons of response proportions based on sUA level
between each lesinurad plus allopurinol group and the
allopurinol-alone group were performed using the
Cochran-Mantel-Haenszel (CMH) test statistic, stratiﬁed by day
−7 renal function and tophus status during screening. A
Bonferroni correction was used for the primary end point for
each of the two treatment comparisons with allopurinol-alone
therapy at an α level of 0.025. Testing of the key secondary end
points hierarchically at an α level of 0.05 was gated on both
dose contrasts being statistically signiﬁcant for the primary end
point. If only one of the primary end point dose contrasts was
signiﬁcant, then α=0.025 for each key secondary end point
within the surviving dose. All other efﬁcacy end points were
evaluated at α=0.05 (nominal p value), two-sided, without
multiplicity adjustment. Results for the primary end point of
sUA response are expressed as proportions and p values.
Patients with missing values at month 6 or month 12 for any
reason were considered non-responders (non-responder imput-
ation, NRI).22 Key secondary end points were analysed using
negative binomial regression (gout ﬂares) or CMH test (tophus
response). Mean rates of gout ﬂares were adjusted for day −7
renal function, tophus status at screening and length of exposure
to randomised study medication. The time points and analytical
methods used in the study were agreed with multiple regulatory
agencies.
Safety data are listed by treatment arm and are not subjected
to statistical testing. TEAEs are coded by system organ class and
preferred term and are listed according to incidence, severity,
relation to study medication and relation to discontinuation. To
better identify potential clinically relevant changes in sCr
related to lesinurad by minimising discrepancies due to intra-
subject variability, baseline sCr was deﬁned as the highest value
within 14 days prior to ﬁrst dose of study medication. Relative
increase in sCr (ie, ≥1.5× and ≥2.0× the baseline level at any
time) was selected as the most clinically relevant sCr
assessment.23 24 Resolution of sCr elevation was deﬁned as an
sCr value returned to ≤1.2× baseline.
A sample size of approximately 600 patients was planned to
be recruited, for an allocation of approximately 200 patients to
each treatment arm. This sample size was calculated to provide
greater than 90% power to detect a difference in response rate
between treatment groups if the allopurinol-alone group had a
30% response rate and the lesinurad groups had response rates
as low as 48% using Fisher’s exact test, adjusting for multiplicity
with α=0.025, two-sided, for each test.
All randomised patients who received at least one dose of
study medication were included in the intent-to-treat (ITT)
population, which was the primary population for efﬁcacy and
safety assessments.
RESULTS
Patient disposition
Of the 2199 patients screened, 611 were randomised at 152
sites. Of the 611 randomised patients, 610 received at least one
dose of study medication (ﬁgure 2).
Demographic characteristics and clinical history
Demographics and baseline disease characteristics were similar
between treatment groups (table 1). Patients generally had long-
standing symptomatic gout (mean (±SD) time since diagnosis
11.5±9.3 years) and elevated baseline sUA (mean 6.9±1.2 mg/dL
(410±71 mmol/L)), with high rates of one or more predeﬁned
comorbidities (ie, CV risk factors or kidney stones) at 79.2%.
Most patients (84.1%) received allopurinol at a daily dose of
300 mg, with 6.6% receiving <300 mg and 9.3% receiving
>300 mg; the overall dose range was 200–900 mg.
Study medications
Proportions of patients exhibiting ≥80% compliance with study
medication were 97.6%, 94.1% and 94.5% in the
allopurinol-alone, lesinurad 200 mg+allopurinol and lesinurad
400 mg+allopurinol groups, respectively.
Efﬁcacy assessments
Primary end point of sUA response and secondary sUA end points
Proportions of patients achieving sUA level of <6.0 mg/dL
(<357 mmol/L) by month 6 (the primary end point) were
23.3%, 55.4% and 66.5% in the allopurinol-alone, lesinurad
200 mg+allopurinol and lesinurad 400 mg+allopurinol groups,
respectively, using NRI—signiﬁcant differences were identiﬁed
for both lesinurad+allopurinol groups versus allopurinol-alone
(p<0.0001; CMH test) (ﬁgure 3).
Subgroup analyses based on age, sex, race, baseline sUA,
comorbidities, renal function and thiazide diuretic use provided
results consistent with primary analysis of the ITT population
(see online supplementary material 4 for renal function and
diuretic analyses).
Proportions of patients achieving the sUA target of
<6.0 mg/dL (<357 mmol/L) were greater in the lesinurad
200 mg+allopurinol and lesinurad 400 mg+allopurinol versus
allopurinol-alone group at all monthly assessments from month 1
to month 12 (nominal p<0.0001, all comparisons). Proportions
of patients achieving sUA level of <5.0 mg/dL (<297 mmol/L)
and <4.0 mg/dL (<238 mmol/L) were also greater in both
lesinurad+allopurinol groups versus allopurinol-alone group at
each monthly visit (sUA <5.0 mg/dL (<297 mmol/L): nominal
p<0.0001, both comparisons; sUA <4.0 mg/dL (<238 mmol/L):
nominal p<0.0001, both comparisons, except p<0.01 at
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month 1, lesinurad 200 mg+allopurinol). Figure 3 shows propor-
tions of patients at each sUA threshold by months 6 and 12.
Mean sUA levels were lower in both lesinurad+allopurinol
groups versus allopurinol-alone group at all time points (nominal
p<0.001, both comparisons compared with allopurinol-alone
therapy) (ﬁgure 4).
Secondary end point: gout ﬂares requiring treatment
The gout ﬂare rate and the proportions of patients with gout
ﬂares requiring treatment were low and similar in all groups
throughout the study. Mean (±SE) rates of gout ﬂares requiring
treatment from the end of month 6 to end of month 12 were
0.83±0.13 for allopurinol-alone group versus 0.73±0.12 and
0.77±0.13, respectively, in the lesinurad 200 mg+allopurinol
and lesinurad 400 mg+allopurinol groups (p=0.57 and 0.75 vs
allopurinol-alone group). Proportions of patients with a gout
ﬂare requiring treatment through the study are shown in online
supplementary ﬁgure S2.
Secondary end point: tophus resolution
The numbers of patients with one or more target tophi at base-
line were low: 33, 35 and 29 in the allopurinol-alone, lesinurad
200 mg+allopurinol and lesinurad 400 mg+allopurinol groups,
respectively. In these respective groups, 33.3%, 31.4% and
27.6% of patients achieved complete resolution of one or more
target tophi by month 12 (p>0.05, both lesinurad+allopurinol
groups vs allopurinol-alone group).
Safety assessments
Adverse events
TEAEs were reported in 70.9%, 74.5% and 80.5% of the
allopurinol-alone, lesinurad 200 mg+allopurinol and lesinurad
400 mg+allopurinol groups, respectively (table 2). The majority
of TEAEs in each group had a maximum severity of grade 1 or
grade 2, based on Rheumatology Common Toxicity Criteria.25
The most common individual TEAEs—reported for
allopurinol-alone, lesinurad 200 mg+allopurinol and lesinurad
400 mg+allopurinol groups, respectively—were upper respira-
tory tract infection (10.2%, 6.9%, 15.0%), hypertension (4.9%,
8.3%, 8.0%), arthralgia (4.4%, 11.8%, 3.0%), increased blood
creatinine (3.4%, 3.9%, 9.5%) and diarrhoea (3.4%, 4.9%,
7.0%). The most common grade 3 or grade 4 TEAEs in these
respective groups were increased blood creatine kinase (1.5%,
0.5%, 1.5%) and myocardial infarction (MI) (0%, 0%, 1.5%).
Serious TEAEs were reported in 3.9%, 4.4% and 9.5%
of patients, respectively (table 2). Two deaths occurred in the
lesinurad 400 mg+allopurinol group (pulmonary oedema and
gastric cancer, respectively). TEAEs led to study-medication dis-
continuation in 5.3%, 3.4% and 9.5% of the allopurinol-alone,
lesinurad 200 mg+allopurinol and lesinurad 400 mg+allopur-
inol groups, respectively; the most common TEAE leading to
discontinuation was increased blood creatinine (1.0%, 0% and
2.5%, respectively).
Renal safety analyses
Renal-related TEAEs occurred in 4.9%, 5.9% and 15.0%, of
allopurinol-alone, lesinurad 200 mg+allopurinol and lesinurad
Figure 2 Patient disposition is shown. aScreened was deﬁned as signing an informed consent form; b2 deaths reported for non-randomised
patients during screening and ccompleted the study with or without completing randomised study medication. One additional death occurred in the
LESU 400 mg+ALLO group. The subject experienced a serious adverse event and withdrew from the study. The primary reason for study withdrawal
was reported as ‘adverse event’. Of the 1538 screen failures, 1183 were related to inclusion criteria, 252 to exclusion criteria, 94 to both inclusion
and exclusion criteria and 9 to other. ALLO, allopurinol; LESU, lesinurad.
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Table 1 Demographic and baseline disease characteristics (intent-to-treat population)
ALLO alone (n=206) Lesinurad 200 mg+ALLO (n=204) Lesinurad 400 mg+ALLO (n=200) Total (n=610)
Sex (n (%))
Male 196 (95.1) 197 (96.6) 194 (97.0) 587 (96.2)
Female 10 (4.9) 7 (3.4) 6 (3.0) 23 (3.8)
Race (n (%))
White 155 (75.2) 167 (81.9) 160 (80.0) 482 (79.0)
Black or African-American 22 (10.7) 15 (7.4) 21 (10.5) 58 (9.5)
Asian 14 (6.8) 10 (4.9) 9 (4.5) 33 (5.4)
Native Hawaiian or other Pacific Islander 5 (2.4) 3 (1.5) 2 (1.0) 10 (1.6)
American-Indian or Alaska Native 1 (0.5) 1 (0.5) 0 2 (0.3)
Other 8 (3.9) 4 (2.0) 6 (3.0) 18 (3.0)
Missing 0 0 1 (0.5) 1 (0.2)
Age (years)
Mean (SD) 51.4 (10.56) 51.0 (11.11) 51.3 (11.08) 51.2 (10.90)
Min, max 21, 80 21, 82 18, 80 18, 82
BMI (kg/m2)
Mean (SD) 33.87 (6.19) 34.67 (6.43) 33.81 (6.68) 34.12 (6.44)
Min, max 21.91, 56.27 22.55, 55.63 22.76, 69.36 21.91, 69.36
Duration since gout diagnosis (years)
Mean (SD) 11.31 (9.38) 12.25 (9.75) 11.02 (8.59) 11.53 (9.26)
Min, max 0.2, 53.0 0.5, 45.0 0.0, 47.4 0.0, 53.0
Presence of tophi at screening (n (%))
Yes 48 (23.3) 49 (24.0) 47 (23.5) 144 (23.6)
No 158 (76.7) 155 (76.0) 153 (76.5) 466 (76.4)
Presence of ≥1 target tophus at baseline (n (%))
Yes 33 (16.0) 35 (17.2) 29 (14.5) 97 (15.9)
No 173 (84.0) 169 (82.8) 171 (85.5) 513 (84.1)
No. of target tophi at baseline
n 33 35 29 97
Mean (SD) 2.2 (1.36) 2.0 (1.34) 2.5 (1.53) 2.2 (1.40)
Min, max 1, 5 1, 5 1, 5 1, 5
No. of gout flares in the past 12 months
Mean (SD) 5.8 (4.92) 6.7 (7.01) 6.1 (5.65) 6.2 (5.93)
Min, max 2, 30 2, 50 2, 48 2, 50
Renal function at baseline (mL/min) (n (%))
eCrCl ≥90 72 (35.0) 80 (39.2) 85 (42.5) 237 (38.9)
eCrCl <90 133 (64.6) 124 (60.8) 114 (57.0) 371 (60.8)
eCrCl ≥60 165 (80.1) 175 (85.8) 170 (85.0) 510 (83.6)
eCrCl <60 40 (19.4) 29 (14.2) 29 (14.5) 98 (16.1)
CV risk factors (n (%))
Hypertension 141 (68.4) 131 (64.2) 121 (60.5) 393 (64.4)
Hyperlipidaemia 76 (36.9) 86 (42.2) 93 (46.5) 255 (41.8)
Type 2 diabetes 28 (13.6) 31 (15.2) 26 (13.0) 85 (13.9)
History of kidney stones (n (%)) 28 (13.6) 23 (11.3) 18 (9.0) 69 (11.3)
Baseline thiazide/thiazide-like
diuretic use (n (%))
37 (18.0) 43 (21.1) 35 (17.5) 115 (18.9)
sUA at baseline (mg/dL) (mmol/L)
Mean (SD) 7.0 (1.3) (416 (75)) 6.8 (1.1) (407 (66)) 6.9 (1.2) (410 (71)) 6.9 (1.2) (410 (71))
Min, max 3.4, 11.3 (202, 672) 4.0, 11.3 (238, 672) 3.8, 11.0 (226, 654) 3.4, 11.3 (202, 672)
sUA category at baseline (n (%))
<8.0 mg/dL (<476 mmol/L) 162 (78.6) 177 (86.8) 164 (82.0) 503 (82.5)
≥8.0 mg/dL (≥476 mmol/L) 44 (21.4) 27 (13.2) 36 (18.0) 107 (17.5)
Continued
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400 mg+allopurinol groups, respectively. The most common
renal-related TEAEs in these respective groups were increased
blood creatinine (3.4%, 3.9%, 9.5%), increased blood urea
(0%, 2.0%, 1.5%) and renal failure (0.5%, 1.0%, 1.5%). One
patient (0.5%) in the allopurinol-alone group experienced a
serious renal-related TEAE, versus no patients in the lesinurad
200 mg+allopurinol and two patients (1.0%) in the lesinurad
400 mg+allopurinol group. Kidney stone TEAEs were reported
in 0.5%, 0% and 3.0%, respectively.
sCr elevation ≥1.5× baseline occurred in 3.4% (n=7), 5.9%
(n=12) and 15.0% (n=30) of allopurinol-alone, lesinurad
200 mg+allopurinol and lesinurad 400 mg+allopurinol groups,
respectively. sCr elevation ≥1.5× was transient and reversible in
most cases and the majority of sCr elevations resolved by the
time of the next assessment; there were three unresolved sCr
elevations in the allopurinol-alone group at last visit versus none
in the lesinurad 200 mg+allopurinol and seven in the lesinurad
400 mg+allopurinol group (see online supplementary table S1).
sCr elevation ≥2.0× baseline occurred in 0%, 2.0% (n=4) and
8.0% (n=16) of patients, respectively. Again, most elevations
≥2.0× baseline were transient and reversible; no sCr elevations
≥2.0× were unresolved at last visit in the lesinurad 200 mg
+allopurinol group and ﬁve cases were unresolved in the lesi-
nurad 400 mg+allopurinol group. In approximately two-thirds
of sCr elevations, resolution occurred while patients continued
on study medication.
In all treatment groups, proportions of patients with an sCr
elevation ≥1.5× baseline tended to be higher for patients (1)
who were taking an NSAID than colchicine; (2) who did not
achieve target sUA at month 6 versus responders and (3) who
had one or more tophi at screening versus those without tophi,
although small subgroup sizes render interpretation difﬁcult (see
online supplementary table S2). There was no apparent associ-
ation between sCr elevation and baseline renal function or other
concomitant medications.
Renal function remained stable across the treatment groups,
as measured by mean (SD) changes in eCrCl, from baseline to
last value. Mean (±SD) changes in eCrCl in the
allopurinol-alone, lesinurad 200 mg+allopurinol and lesinurad
400 mg+allopurinol groups were 3.0±9.7, −0.5±11.5 and
−5.7±13.9 mg/dL, respectively, from baseline to last value on
treatment and were 1.8±11.7, 2.7±10.0 and 1.1±24.2 mg/dL
from baseline to last value off treatment at follow-up (in patients
not entering a separate extension study, n=133).
CV safety analyses
TEAEs were adjudicated as CV events in 5.3% (n=11 patients),
3.9% (n=8 patients) and 3.0% (n=6 patients) of
allopurinol-alone, lesinurad 200 mg+allopurinol and lesinurad
400 mg+allopurinol groups, respectively. CEAC-adjudicated cri-
teria for MACE were met by three patients (four events, includ-
ing three MIs and one death due to pulmonary oedema), all in
Table 1 Continued
ALLO alone (n=206) Lesinurad 200 mg+ALLO (n=204) Lesinurad 400 mg+ALLO (n=200) Total (n=610)
Type of gout flare prophylaxis at baseline (n (%))
Colchicine 159 (77.2) 181 (88.7) 167 (83.5) 507 (83.1)
NSAID 51 (24.8) 23 (11.3) 36 (18.0) 110 (18.0)
Both 8 (3.9) 4 (2.0) 3 (1.5) 15 (2.5)
Other or missing 4 (1.9) 4 (2.0) 0 8 (1.3)
Allopurinol dose at baseline (mg/day)
Mean (SD) 308.7 (69.29) 313.5 (78.33) 314.8 (77.62) 312.3 (75.08)
Min, max 200, 600 200, 900 200, 900 200, 900
ALLO, allopurinol; BMI, body mass index; CV, cardiovascular; eCrCl, estimated creatinine clearance; NSAID, non-steroidal anti-inflammatory drug; sUA, serum uric acid.
Figure 3 Proportions of patients achieving sUA target of <6.0 mg/dL (<357 mmol/L), <5.0 mg/dL (<297 mmol/L) and <4.0 mg/dL (<238 mmol/L),
by months 6 and 12 (ITT population) are shown. Primary end point: proportion of patients achieving sUA target of <6.0 mg/dL (<357 mmol/L) by
month 6. *p<0.0001. Note: Subjects missing sUA results were treated as non-responders. All comparisons used a two-sided Cochran-Mantel-
Haenszel test stratiﬁed by day −7 renal function and tophus status during screening (randomised stratiﬁcation factor values), with non-responder
imputation and adjustment for multiple comparisons for the primary end point (Bonferroni correction). ALLO, allopurinol; ITT, intention to treat;
LESU, lesinurad; sUA, serum uric acid.
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the lesinurad 400 mg+allopurinol group. Non-MACE CV end
points were reported in ﬁve patients (ﬁve events), two patients
(two events) and no patients, respectively.
Other clinical laboratory tests and vital signs
Clinical laboratory results (excluding renal laboratory results,
reported above) and urinalysis were comparable between treat-
ment groups. Elevations in creatine kinase >5× upper limit of
normal were in 5.3%, 2.0% and 3.0% of allopurinol-alone, lesi-
nurad 200 mg+allopurinol and lesinurad 400 mg+allopurinol
groups, respectively. There were no notable changes in vital signs.
DISCUSSION
Allopurinol at the 300 mg dose is frequently unable to achieve
target sUA levels.5–8 Guidelines recommend increasing the allo-
purinol dose above 300 mg/day to attain target sUA, but this
happens rarely in practice, in part due to physician’s concerns
over safety of doses >300 mg.4 6 25–29 Other management
options include switching from allopurinol to febuxostat, or
adding a uricosuric to allopurinol, based on evidence from
earlier, small trials.30–32 CLEAR 2 and the similarly designed
CLEAR 115 were the initial large studies to validate a combin-
ation approach using a URAT1 inhibitor that inhibits uric acid
reabsorption (ie, lesinurad) with allopurinol.
In CLEAR 2, lesinurad at both doses (200 or 400 mg) com-
bined with continued allopurinol signiﬁcantly increased the pro-
portions of patients achieving sUA target of <6.0 mg/dL
(<357 mmol/L) by month 6 (p<0.0001), with more than twice
as many patients reaching goal versus allopurinol-alone therapy.
Onset of sUA reduction in the lesinurad groups was rapid, with
signiﬁcant differences from allopurinol-alone group by ﬁrst
assessment at month 1. The signiﬁcant increase in proportions
of patients who achieved sUA target in both lesinurad+allopur-
inol groups versus allopurinol-alone group was sustained over
the 12-month study. Consistent response rates were observed,
irrespective of renal function or thiazide diuretic use.
There were no statistically signiﬁcant differences favouring
lesinurad treatment in the rates of gout ﬂare requiring treatment
or complete resolution of tophi, which occurred at low inci-
dences at baseline and during study. In relation to these key
secondary end points, treatment may be required for more than
12 months for the full effects to be observed.33
Lesinurad was generally well tolerated, particularly at the
200 mg dose, where the TEAE and serious TEAE proﬁles were
comparable with the allopurinol-alone group. Higher TEAE
incidences were seen in the lesinurad 400 mg+allopurinol
group. Renal-related TEAEs occurred at similar incidences in
the lesinurad 200 mg+allopurinol and allopurinol-alone groups,
with a higher incidence in the lesinurad 400 mg+allopurinol
than lesinurad 200 mg+allopurinol group; the lesinurad
400 mg+allopurinol group also showed a higher incidence of
sCr elevation. The majority of sCr elevations resolved by the
next assessment and in most cases without interruption in study
medication. Mean renal function did not differ between the
treatment groups both before and after treatment. The mechan-
ism of sCr elevation associated with lesinurad may be via
increased excretion of urinary uric acid, which has the potential
to induce uric acid microcrystallisation in the renal tubules.
Urine protein-to-creatinine ratio and urinalyses did not change
during the study, suggesting that sCr elevation was not asso-
ciated with renal parenchymal sequelae. Patients with unre-
solved sCr elevations showed no deﬁning characteristics
compared with those whose sCr elevation resolved.
Other therapies which inhibit URAT1 have been associated
with development of kidney stones.34 35 The lack of increase in
kidney stone numbers during lesinurad therapy is potentially
because of concomitant allopurinol use, which reduces uric acid
production.36 37 The rate of nephrolithiasis may also have been
inﬂuenced by timing of lesinurad administration, as once-daily
dosing in the morning increases urinary uric acid at a time when
urine volume and urine pH are highest and the potential for
uric acid precipitation is lowest.38 39
Prescribing information for the approved dose of lesinurad
200 mg recommends assessment of renal function prior to initi-
ation of therapy and periodically thereafter, particularly in
patients whose CrCl is 30–<45 mL/min, with discontinuation
recommended if CrCl is persistently <30 mL/min (ie, severe
renal impairment). Lesinurad is also contraindicated in subjects
with end-stage renal disease, kidney transplant recipients or
patients on dialysis.
Figure 4 Graph showing the mean
(SE) sUA levels by visit (observed
cases, intent-to-treat population).
Mean change from baseline for each
active treatment group was compared
with the ALLO-alone group using
analysis of covariance, with p<0.001
at each time point. ALLO, allopurinol;
LESU, lesinurad; sUA, serum uric acid.
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CV comorbidities and risk factors were present in approxi-
mately 80% of patients, reﬂecting the high rates of CV disease
in patients with gout.40–42 The proportions of patients with
TEAEs classiﬁed as CV events during study were low and similar
in treatment groups. Incidences of MACE events—that is,
serious CV events including CV deaths, non-fatal MI and non-
fatal stroke—were similarly low. Three patients experienced
MACE in the study, all receiving lesinurad 400 mg. Low rates of
MACE events during gout treatment were also reported in the
open-label Long-term Allopurinol Safety Study Evaluating
Outcomes in Gout Patients (LASSO) study, which reported a
rate of 0.58% over 6 months for MACE during allopurinol
treatment (incidence rate 1.42/100 patient-years).6
Limitations of CLEAR 2 include the limited data on allopur-
inol doses >300 mg, the relatively low proportion of women
enrolled, low number of patients with evaluable tophi and the
relatively short-term follow-up period that limits the ability to
adequately study ﬂares and tophi. Rates of gout ﬂares and
tophus resolution over the longer term are being investigated in
an extension study (NCT01808131).
In conclusion, lesinurad (200 and 400 mg), a novel SURI, in
combination with allopurinol signiﬁcantly increased the propor-
tion of patients achieving the target sUA of <6.0 mg/dL
(<357 mmol/L) by month 6 and other sUA end points compared
with allopurinol-alone therapy. There were no statistically
signiﬁcant treatment-group differences favouring lesinurad for
rate of gout ﬂares or complete tophus resolution. The combin-
ation therapy was generally well tolerated, particularly at the
200 mg lesinurad dose approved by the US Food and Drug
Administration and European Medicines Agency, except for
higher incidences of predominantly reversible sCr elevation
compared with allopurinol-alone therapy. There were no cases
of unresolved sCr elevation ≥1.5× in the lesinurad 200 mg
+allopurinol group, versus three unresolved cases in the
allopurinol-alone group and seven in the lesinurad 400 mg
Table 2 Overall summary of TEAEs (safety population)
Adverse event
category, n (%)
ALLO
alone
(n=206)
Lesinurad 200
mg+ALLO
(n=204)
Lesinurad 400
mg+ALLO
(n=200)
Any TEAE 146 (70.9) 152 (74.5) 161 (80.5)
Any TEAE with RCTC
toxicity grade 3 or 4
23 (11.2) 19 (9.3) 27 (13.5)
Any TEAE possibly related
to randomised study
medication
39 (18.9) 40 (19.6) 50 (25.0)
Any serious TEAE 8 (3.9) 9 (4.4) 19 (9.5)
Any fatal TEAE 0 0 2 (1.0)
Any TEAE leading to
randomised study
medication discontinuation
11 (5.3) 7 (3.4) 19 (9.5)
Any TEAE leading to study
withdrawal
7 (3.4) 4 (2.0) 12 (6.0)
Individual serious TEAEs,
n (%)
Infections and infestations
Pneumonia 0 2 (1.0) 0
Bronchopneumonia 0 0 1 (0.5)
Cellulitis 0 0 1 (0.5)
Empyema 0 1 (0.5) 0
Pyelonephritis chronic 0 0 1 (0.5)
Sinobronchitis 0 1 (0.5) 0
Abscess limb 1 (0.5) 0 0
Appendicitis 1 (0.5) 0 0
Diverticulitis 1 (0.5) 0 0
Neoplasms benign, malignant and unspecified
Basal cell carcinoma 0 0 1 (0.5)
Gastric cancer 0 0 1 (0.5)*
Ovarian adenoma 0 1 (0.5) 0
Parathyroid tumour
benign
0 1 (0.5) 0
Prostate cancer 0 0 1 (0.5)
Pancreatic
neuroendocrine tumour
1 (0.5) 0 0
Metabolism and nutrition disorders
Gout flare 0 0 2 (1.0)
Psychiatric disorders
Depression 0 1 (0.5) 0
Dissociative disorder 0 0 1 (0.5)
Nervous system disorders
Subarachnoid
haemorrhage
1 (0.5) 0 0
Cardiac disorders
Myocardial infarction 0 0 3 (1.5%)
Atrial fibrillation 0 1 (0.5) 0
Coronary artery disease 0 0 1 (0.5)
Intracardiac thrombus 0 0 1 (0.5)
Vascular disorders
Hypertensive crisis 0 0 1 (0.5)
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema 0 0 1 (0.5)*
Gastrointestinal disorders
Duodenal ulcer
haemorrhage
1 (0.5) 0 1 (0.5)
Gastrointestinal
haemorrhage
0 1 (0.5) 0
Continued
Table 2 Continued
Adverse event
category, n (%)
ALLO
alone
(n=206)
Lesinurad 200
mg+ALLO
(n=204)
Lesinurad 400
mg+ALLO
(n=200)
Musculoskeletal and connective tissue disorders
Osteoarthritis 0 0 2 (1.0)
Arthralgia 0 1 (0.5) 0
Back pain 0 1 (0.5) 0
Flank pain 0 1 (0.5) 0
Intervertebral disc
degeneration
0 0 1 (0.5)
Renal and urinary disorders
Nephrolithiasis 0 0 2 (1.0)
Renal failure acute 1 (0.5) 0 1 (0.5)
Renal impairment 0 0 1 (0.5)
General disorders and administration site conditions
Adverse drug reaction 0 1 (0.5) 0
Non-cardiac chest pain 0 1 (0.5) 0
Injury, poisoning and procedural complications
Multiple drug overdose 0 1 (0.5) 0
Multiple injuries 0 1 (0.5) 0
Femur fracture 1 (0.5) 0 0
*Fatal serious TEAE.
ALLO, allopurinol; RCTC, Rheumatology Common Toxicity Criteria; TEAE,
treatment-emergent adverse event.
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+allopurinol group. By using a dual mechanism approach to
reduce sUA, combination therapy with lesinurad and allopurinol
represents a treatment option for patients with gout inad-
equately controlled on allopurinol-alone therapy.
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